Machine Learning and Pan‐Cancer Analysis of Tertiary Lymphoid Structures: A Potential Target for Survival and Drug Treatment

Jianguo Lai,Yuchen Cao,Jiexin Zhang,Jinglong Wang,Yawen Du,Yan He,Yuting Luo,Ning Liao

DOI: https://doi.org/10.1002/adtp.202300003

IF: 5.003

2023-05-19

Advanced Therapeutics

Abstract:Tertiary lymphoid structure (TLS) is considered to be closely related to tumor prognosis and immune response. Therefore, it has predictable clinical significance for survival prognosis and cancer drug treatment to build TLS signature of pan‐cancer. The transcriptome sequencing data of The Cancer Genome Atlas pan‐cancer analysis are obtained from UCSC Xena, including 33 cancer types (N = 10 066). A 15 TLS genes‐based TLSscore is constructed using the Random Forest and Cox regression analyses. Then, according to TLS signature, patients are classified into low‐ and high‐risk groups. Then, the differences between the two groups in terms of survival prognosis, functional enrichment, immune infiltration, and drug sensitivity are further explored. On the basis of machine learning algorithm, TLS signature has satisfactory prediction performance for the prognosis of pan‐cancer patients. A nomogram with high predictive performance is formulated by incorporating TLS signature and clinical features. The function enrichment analysis suggests that TLS signature may be related to the key pathways of immunotherapy for pan‐cancer, and shows significant differences among groups at the immune checkpoint genes. In general, a novel TLSscore‐based model is established through comprehensive analysis of TLS genes, which can accurately predict the clinical prognosis and drug sensitivity of pan‐cancer. Tertiary lymphoid structure (TLS) is considered to be closely associated with tumor prognosis and immune response. This study aims to present a systematic assessment of TLS signature in pan‐cancer datasets by defining TLS score with 15 selected genes. A novel TLS model is established to predict the survival prognosis and guide to choose optimal drug treatment strategy.